Recent fatalities in gene therapy clinical trials in China have prompted two U.S. lawmakers to advocate for stricter policies from the FDA aimed at safeguarding American patients.
Following three reported deaths in separate clinical trials, Representatives John Moolenaar (R-MI) and Ben Cline (R-VA) have reached out to Acting FDA Commissioner Kyle Diamantas. They express concerns that accepting clinical data from China poses significant risks to patients in the U.S.
Legislative Action
In their correspondence, the lawmakers have requested that the FDA reject any clinical data sourced from China unless the trial site has undergone a recent FDA audit. They are also calling for a comprehensive review of products that received U.S. approval based on Chinese clinical results. This appeal underscores the lawmakers’ belief that offshoring early-stage clinical trials to China can inadvertently endorse a system that may prioritize speed and cost over patient safety.
Recent Fatalities
The issue gained traction after three patient deaths linked to gene therapy trials in China were reported in recent months. One notable case involved a young boy with Duchenne muscular dystrophy (DMD) who died after participating in a study involving HuidaGene’s CRISPR-based therapy, HG302. The biotech company stated that the child experienced acute respiratory distress syndrome following the high-dose administration of an adeno-associated virus vector.
Further complicating matters, RiboX Therapeutics reported a death in a patient with systemic sclerosis who had undergone their experimental in vivo CAR T cell therapy. The company emphasized the patient’s significant pre-existing conditions, stating that any causal link between the treatment and death needs to be evaluated by the principal investigator.
Investigative Actions
Additionally, a six-year-old girl receiving the first gene-editing therapy for a genetic neurodevelopmental disorder died one week after treatment. This incident, which involved a severe immune response, has led to an internal investigation by Xinhua Hospital, associated with Shanghai Jiao Tong University.
These deaths have intensified scrutiny on China’s biotech sector, raising questions about national security and innovation. Such concerns are compounded by the U.S. government’s recent initiatives aimed at modernizing clinical trials to bring more research back to American soil.
Challenges of Modernization
Despite these initiatives, experts caution that they may not sufficiently address the core issues affecting trial delays. Harpreet Singh, a former FDA oncology division director, noted that most delays occur at the site level rather than due to FDA regulations. Trials conducted in countries like Spain or Australia often demonstrate quicker timelines and lower administrative burdens compared to those in the U.S.
The Rise of China’s Trials
The dynamics of clinical trials have shifted significantly. In 2010, less than 8% of global trials were conducted in China. By 2020, the country had surpassed the U.S. in the number of annual registered trials. China’s National Medical Products Administration has also outpaced the FDA regarding cancer drug approvals, with 94 oncology drugs approved from 2020 to 2025, compared to 87 in the U.S.
Conclusion
The recent fatalities in gene therapy trials highlight pressing concerns about patient safety and regulatory oversight in international clinical research. As lawmakers push for stricter FDA policies, the landscape of clinical trials continues to evolve, necessitating careful scrutiny and proactive measures to ensure American patients’ safety. The dialogue surrounding these issues may shape the future of biotech and gene therapy development both domestically and abroad.
- Takeaway Points:
- U.S. lawmakers are advocating for stricter FDA policies following deaths in Chinese clinical trials.
- Concerns about patient safety have led to calls for audits and reviews of clinical data from China.
- The shift of clinical trials to China raises questions about regulatory oversight and the safety of treatments.
Read more → www.biospace.com